CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionDebt-to-equity is 1.43×, higher than 95% of its Medical Devices peers (median 0.11×)
- FinancialsAltman Z-Score -3.2: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
627.15MUSDvs all stocks (USD)
Revenue (TTM)
216.56MUSDvs all stocks (USD)
Profit Margin
-4.41%vs Medical Devices peers
Beta
1.77xvs all stocks
52-Week Change
126.81%vs all stocks
Market Capitalization
627.15MUSDvs all stocks (USD)
Enterprise Value
654.84MUSDvs all stocks (USD)
Forward P/E
-90.67xvs Medical Devices peers
Price to Sales (TTM)
2.97xvs Medical Devices peers
Price to Book (MRQ)
9.53xvs Medical Devices peers
Enterprise to Revenue
3.02xvs Medical Devices peers
Gross Margin
51.98%vs Medical Devices peers
Profit Margin
-4.41%vs Medical Devices peers
Operating Margin
-0.66%vs Medical Devices peers
Return on Assets (TTM)
-0.93%vs Medical Devices peers
Return on Equity (TTM)
-15.37%vs Medical Devices peers
Revenue (TTM)
216.56MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.13USDUpdated Jul 18, 2026Quarterly Revenue Growth
24.10%vs Medical Devices peers
Gross Profit (TTM)
114.76MUSDvs all stocks (USD)
EBITDA (TTM)
-1.62MUSDvs all stocks (USD)
Net Income (TTM)
-9.55MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
24.10%vs Medical Devices peers
Operating Cash Flow (TTM)
2.63MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
2.26MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Minority Interest (Equity)
741.00KUSDFY2025 · Dec 31, 2025Revenue
206.13MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
93.84MUSDFY2025 · Dec 31, 2025Gross Profit
112.29MUSDFY2025 · Dec 31, 2025Operating Income
-8.68MUSDvs all stocks (USD)
Pre-tax Income
-15.28MUSDFY2025 · Dec 31, 2025Income Tax Expense
354.00KUSDFY2025 · Dec 31, 2025Net Income
-15.64MUSDFY2025 · Dec 31, 2025EBIT
-6.94MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-4.24MUSDFY2025 · Dec 31, 2025Research & Development
67.72MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
80.91MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-27.66MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
8.34MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.0800USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.0800USDFY2025 · Dec 31, 2025Basic Shares Outstanding
190.59MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
190.59MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-15.64MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
10.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
2.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
20.60MUSDFY2025 · Dec 31, 2025Income Tax Paid
301.00KUSDFY2025 · Dec 31, 2025Interest Paid
8.52MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-15.64MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.43MUSDFY2025 · Dec 31, 2025Stock-based Compensation
22.87MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.93MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-396.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
5.72MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-14.81MUSDFY2025 · Dec 31, 2025Purchase of Investments
-42.78MUSDFY2025 · Dec 31, 2025Sale of Investments
40.34MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.44MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-329.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-35.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-364.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
200.32MSharesUpdated Jul 18, 2026Float Shares
182.92MSharesUpdated Jul 18, 2026Shares Short
12.74MSharesUpdated Jul 18, 2026Short Ratio
4.67daysvs all stocks
Short % of Shares Outstanding
6.55%vs all stocks
% Held by Insiders
3.40%vs all stocks
% Held by Institutions
73.30%vs all stocks
Total Cash (MRQ)
80.42MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.4010USDUpdated Jul 18, 2026Total Debt (MRQ)
97.36MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.43xvs Medical Devices peers
Current Ratio (MRQ)
1.63xvs Medical Devices peers
Book Value per Share (MRQ)
0.3370USDUpdated Jul 18, 2026Total Assets
221.86MUSDvs all stocks (USD)
Total Current Assets
174.38MUSDFY2025 · Dec 31, 2025Total Liabilities
156.89MUSDFY2025 · Dec 31, 2025Total Non-current Assets
47.48MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
56.09MUSDFY2025 · Dec 31, 2025Total Current Liabilities
100.80MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
19.96MUSDFY2025 · Dec 31, 2025Other Short-term Investments
62.92MUSDFY2025 · Dec 31, 2025Accounts Receivable
30.37MUSDFY2025 · Dec 31, 2025Inventory
56.10MUSDFY2025 · Dec 31, 2025Accounts Payable
28.01MUSDFY2025 · Dec 31, 2025Short-term Debt
46.25MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.27MUSDFY2025 · Dec 31, 2025Long-term Debt
50.70MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
5.39MUSDFY2025 · Dec 31, 2025Common Stock (Book)
192.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.08BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
64.97MUSDvs all stocks (USD)
52-Week Low
1.15USDUpdated Jul 18, 202652-Week High
3.47USDUpdated Jul 18, 202652-Week Change
126.81%vs all stocks
Beta
1.77xvs all stocks
50-Day MA
2.76USDUpdated Jul 18, 2026200-Day MA
2.15USDUpdated Jul 18, 2026Avg 10-Day Volume
2.11MSharesUpdated Jul 18, 2026Avg 30-Day Volume
2.61MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.0500USDUpdated Jul 18, 2026Other Income / Expense
1.74MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 1.43×, higher than 95% of its Medical Devices peers (median 0.11×)Significant
Debt-to-equity: 1.43Industry median: 0.11Industry P95: 1.20Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.52Profit Margin: -0.04
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 1.63Altman Z-Score: -3.20
Financial Health
Altman Z-Score -3.2: distress zoneCritical
Altman Z-Score: -3.20
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Jinling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Kinetic Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lanzhou Foci Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Weixinkang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gkht Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou AGS Medtech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ironwood Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kexing Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
TTY Biopharm Company Limited
Tier 1ProductionApproval-Gated PipelineRule
Beijing Scitop Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shandong Longda Meishi Co., Ltd.
2 interpretationsWithin or Near the Altman Distress ZoneElevated Leverage on Three Denominators
China High-Speed Railway Co., Ltd.
2 interpretationsWithin or Near the Altman Distress ZoneElevated Leverage on Three Denominators
Yorhe Fluid Intelligent Control Co., Ltd.
2 interpretationsWithin or Near the Altman Distress ZoneElevated Leverage on Three Denominators